Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 213.48M | 56.37M | 7.44M | 4.71M | 5.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 213.48M | 56.37M | 7.44M | 4.71M | 5.55M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 213.48M | 56.37M | 7.44M | 4.71M | 5.55M |
| SG&A Expenses | 12.65M | 13.28M | 11.43M | 11.13M | 10.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.71M | 60.02M | 57.79M | 51.13M | 47.59M |
| Operating Income | 158.77M | -3.65M | -50.36M | -46.42M | -42.04M |
| Income Before Tax | 165.11M | 2.28M | -43.72M | -39.34M | -34.60M |
| Income Tax Expenses | 2.27M | -1.50M | 666.00K | -- | 172.00K |
| Earnings from Continuing Operations | 162.85M | 3.78M | -44.38M | -39.34M | -34.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 162.85M | 3.78M | -44.38M | -39.34M | -34.77M |
| EBIT | 158.77M | -3.65M | -50.36M | -46.42M | -42.04M |
| EBITDA | 159.16M | -3.24M | -49.98M | -46.06M | -41.74M |
| EPS Basic | 2.47 | 0.06 | -0.69 | -0.62 | -0.55 |
| Normalized Basic EPS | 1.57 | 0.02 | -0.43 | -0.39 | -0.34 |
| EPS Diluted | 2.29 | 0.05 | -0.70 | -0.62 | -0.55 |
| Normalized Diluted EPS | 1.45 | 0.02 | -0.43 | -0.39 | -0.34 |
| Average Basic Shares Outstanding | 65.94M | 65.09M | 64.03M | 63.77M | 63.51M |
| Average Diluted Shares Outstanding | 71.01M | 70.49M | 64.03M | 63.77M | 63.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |